The 60-Day Fix: A Temporary Nerve Zap Offers Years of Pain Relief

CLEVELAND, OH – July 07, 2026 – In the relentless and often dispiriting world of chronic pain management, the prevailing logic has long been one of escalation. Patients move from pills to more invasive procedures, a conveyor belt leading toward permanent implants or surgery. A new body of evidence, however, suggests a powerful counter-narrative: a temporary, 60-day treatment that provides years of sustained relief, effectively stopping the conveyor belt in its tracks.

SPR, a Cleveland-based medical device firm, has published compelling long-term data for its SPRINT Peripheral Nerve Stimulation (PNS) System. The study, featured in the journal Pain and Therapy, followed 602 real-world patients with chronic low back pain. The results are striking: an overwhelming 79 percent of those who initially responded to the 60-day treatment successfully avoided subsequent, more invasive interventions—including radiofrequency ablation, permanent neurostimulators, and back surgery—for follow-up periods stretching from six months to over five years.

This isn't just another incremental improvement in a crowded field. It's a fundamental challenge to the treatment continuum itself. The data suggests that a short-term, minimally invasive intervention can potentially “recondition” the central nervous system, offering a durable off-ramp from a life of chronic pain and escalating medical procedures. For millions suffering from intractable low back pain, this quiet move in the med-tech space could represent a seismic shift in their quality of life.

A New Blueprint for Pain Management

The SPRINT PNS System operates on a principle that is both innovative and refreshingly straightforward. Unlike permanent spinal cord stimulators (SCS) that require surgical implantation of a device for life, the SPRINT system is temporary. For 60 days, one or two hair-thin wires are placed under the skin near the targeted peripheral nerve. These wires connect to a small, wearable stimulator worn externally, which delivers mild electrical pulses. After the treatment period, the wires are withdrawn without a trace, leaving no permanent implant behind.

The strategic rationale is to interrupt the pain cycle and provide the central nervous system a chance to reset. The company proposes this as a “First-Line PNS™” option, a tool to be used before resorting to nerve destruction or permanent hardware. This approach directly confronts the opioid crisis by offering a drug-free alternative and gives patients a minimally invasive option before they commit to life-altering surgeries.

The real-world impact of this approach is profound. The study highlighted that the benefits extended beyond just pain reduction, with patients reporting improvements in quality of life, physical function, mood, and sleep. As lead author and SPR consultant Dr. Samir Sheth noted, “The multi-dimensional nature of the improvements we observed... reflects how meaningfully this treatment can impact patients’ lives.”

This stands in stark contrast to the traditional pathway. Patients often endure years of opioid prescriptions, with their attendant risks of addiction and diminishing efficacy. When that fails, they may face radiofrequency ablation (using heat to destroy nerve tissue) or the daunting prospect of spinal surgery. The SPRINT system inserts a new, powerful option into this timeline, one that promises not just relief, but avoidance. The data backs this up: of the patients in the survey actively trying to avoid surgery, a remarkable 95 percent were successful.

The Data That's Shifting a Paradigm

A single press release can be easily dismissed as marketing, but the evidence supporting SPRINT's efficacy is becoming a significant body of work. The latest publication in Pain and Therapy is not an outlier but rather the capstone on a growing mountain of clinical and real-world data. This consistency is what gives the technology its strategic leverage in the medical community.

Beyond the headline figure of 79 percent avoiding interventions, the specifics are even more compelling. For patients who were specifically trying to sidestep a permanent neurostimulator implant—a costly and invasive commitment—92 percent succeeded thanks to the 60-day SPRINT treatment. This finding directly challenges the long-held belief that a successful trial of a neurostimulator must inevitably lead to a permanent implant.

This large survey is consistent with other, more focused studies. One four-year follow-up of SPRINT patients found that 70% of respondents maintained clinically significant pain relief and functional improvement, avoiding more invasive interventions years after their initial 60-day treatment. While that study did not specifically analyze long-term safety outcomes, a broader retrospective review of over 6,100 patients found a low rate of medical events, with minor skin irritation being the most common complaint. This growing portfolio of evidence, backed by what SPR calls the largest body of clinical evidence in the PNS field, is crucial for securing buy-in from physicians, insurers, and hospital administrators.

“For patients who respond to SPRINT PNS, these data suggest they stand a strong chance of experiencing long-term benefits, avoiding additional interventions down the road,” Dr. Sheth explained, underscoring the predictive power of a positive initial response.

Reshaping the Neuromodulation Market

The clinical validation is translating into significant commercial momentum, a flow of capital and influence that is reshaping the competitive landscape. SPR, a privately held company founded in 2010, has been executing a deliberate strategy of building clinical evidence to drive commercial adoption. This culminated in a February 2024 financing round of $85 million to fuel further expansion.

The market has taken notice. In a move that validates SPR's entire approach, medical device titan Medtronic announced its intent to acquire the company in May 2026. This is a classic strategic play: the established giant acquiring the nimble innovator to fill a critical gap in its portfolio. Medtronic, along with Abbott and Boston Scientific, dominates the market for permanent neurostimulators. By acquiring SPR, Medtronic gains a best-in-class temporary PNS system, allowing it to engage patients much earlier in their pain journey and offer a less invasive, non-permanent solution.

This acquisition signals a broader shift in the multi-billion-dollar neuromodulation market. The focus is expanding from purely long-term solutions to a more nuanced, tiered approach. The SPRINT system doesn't necessarily replace permanent implants but creates a new, high-efficacy category for those who may not need—or want—a lifetime device.

For SPR’s founder, President, and CEO, Maria Bennett, this validates a vision that began as a master's thesis. “The potential for a patient seeking to avoid further interventions and more invasive care to find relief through a 60-day treatment is significant,” she stated. This new data, demonstrating sustained relief for over five years in some cases, reinforces the core belief that SPRINT PNS can and should be used early in the treatment continuum, fundamentally altering the path for millions of chronic pain sufferers.